Asset profile
TRN501
Small molecule
Evidence outlook · lead readout
NCT06453551 · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06453551: This was a randomized, double-blind, placebo-controlled study, a sound design for an early safety trial, but it was conducted in healthy volunteers with only safety endpoints, and results are not yet posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.